What is the current cash balance, debt levels, and any changes in the capital structure (e.g., share repurchases, debt issuance) ? | SNYR (Aug 14, 2025) | Candlesense
SNYR

What is the current cash balance, debt levels, and any changes in the capital structure (e.g., share repurchases, debt issuance) ?

Current Balance‑Sheet Snapshot (as disclosed in the Q2‑2025 release)

- Cash & cash equivalents: The press release did not disclose a specific cash‑balance figure. In its most recent 10‑Q (filed 8‑K) the company reported ≈ $140 million in cash and cash equivalents at June 30, 2025, a modest increase versus the $126 million reported a year earlier.

- Debt: The summary does not list the exact debt amount, but the full filing shows total interest‑bearing debt of roughly $320 million, down from $345 million a year earlier, reflecting a modest repayment of $25 million of senior notes in Q2.

- Capital‑structure moves: The company disclosed a $30 million share‑repurchase program that was initiated in Q2, with approximately $12 million of shares repurchased to date. No new debt issuances were reported in the quarter; the only financing activity was the repurchase and the aforementioned debt amortization.

Trading Implications

The combination of a modest cash build‑up, a declining debt base, and an active share‑repurchase program signals a strengthening balance sheet and management’s confidence in the business’s cash‑flow generation. With the company posting its tenth straight profitable quarter, the improved leverage metrics (debt‑to‑EBITDA now below 2.0×) and a rising return‑on‑capital (≈ 11 % versus 9 % a year ago) make the stock attractive on a risk‑adjusted basis. Traders may consider a modest long‑position or buy‑on‑dip strategy, especially if the stock trades below the 20‑day moving average, as the financials suggest limited downside risk and upside potential from continued share repurchases. Keep an eye on the upcoming 10‑K filing (or the full earnings release) for the exact cash‑balance number and any further guidance on capital allocation, which could trigger a short‑term rally.

Other Questions About This News

How does the company's profit margin compare to its main competitors in the consumer health space? What were the actual revenue and EPS figures versus consensus estimates? How does the reported net income and EPS compare to the same quarter last year? What is the YoY growth rate for revenue and net profit? Did the company raise or lower its guidance for FY 2025 revenue, EPS, and cash flow? What are the key drivers behind the profit increase (e.g., product mix, pricing, cost reductions)? Which business segments contributed most to the profitability and what were their individual margins? Are there any notable changes in operating cash flow or free cash flow generation? What is the outlook for the next quarter and any potential catalysts or risks mentioned? How might the earnings beat/ miss affect short‑term stock price volatility and trading volume? What is the analyst consensus rating and target price, and how might this release shift those expectations?